CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
CellProthera is developing a novel cell therapy to prevent heart failure following acute myocardial infarction. Their approach utilizes patented technology to expand stem cells, aiming to provide a less invasive and more cost-effective treatment option with significant potential for patient recovery.
Heart failure (HF) after acute myocardial infarction (AMI) remains the first cause of death in developed countries, above cancer, with a life expectancy less than 5 years.
With an overall cost of 83 billion euros per year worldwide , HF represents a global public-health issue.
Treatments following AMI are still characterised by burdensome surgical procedures and post-operative treatments which both fail to prevent HF development.
In this context, CellProthera, founded in 2008, developed an innov…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
